Peter Kent Hawryluk's most recent trade in MBX Biosciences Inc. was a trade of 18,500 Common Stock done at an average price of $28.4 . Disclosure was reported to the exchange on March 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 28.41 per share. | 13 Mar 2026 | 18,500 | 486,777 | - | 28.4 | 525,663 | Common Stock |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 26 Feb 2026 | 28,768 | 728,274 | - | 16 | 460,288 | Common Stock |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 28,768 | 91,668 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 164,500 | 164,500 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 35,250 | 699,506 | - | 0 | Common Stock | |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Oct 2025 | 182,859 | 129,708 | - | - | Stock option (right to buy) | |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.25 per share. | 24 Oct 2025 | 182,859 | 664,256 | - | 3.3 | 594,292 | Common Stock |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 13.64 per share. | 20 Oct 2025 | 20,000 | 468,277 | - | 13.6 | 272,790 | Common Stock |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 243,000 | 243,000 | - | - | Stock Option (Right to Buy) | |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 10.69 per share. | 03 Feb 2025 | 50,000 | 448,277 | - | 10.7 | 534,500 | Common Stock |
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 2,015,681 | 0 | - | - | Series A Convertible Preferred Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 1,396,762 | 0 | - | - | Series B Convertible Preferred Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 970,873 | 0 | - | - | Series C Convertible Preferred Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 345,705 | 0 | - | - | Series A Convertible Preferred Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 283,846 | 481,397 | - | - | Common Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 115,914 | 398,277 | - | - | Common Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | 16 Sep 2024 | 76,969 | 0 | - | - | Series B Convertible Preferred Stock | ||
| MBX Biosciences Inc | Peter Kent Hawryluk | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 120,436 | 120,436 | - | - | Stock Option (Right to Buy) |